The Europe Spinal Muscular Atrophy Treatment Market should witness market growth of 18.1% CAGR during the forecast period (2022-2028).
Depending on the shape and kind of SMA, the prognosis varies. Certain kinds are lethal if left untreated. Long periods of stability may be apparent in a person, but without therapy, improvement cannot be anticipated. While some SMA patients pass away in infancy, others can survive into adolescence or early adulthood.
For infants with SMA Type I, the majority pass away within the initial two years. The prognosis for average lifespan or independent walking or standing in individuals with SMA Type II approximately coincides with the age at which symptoms first appear, older children typically have less serious symptoms. Although the average lifespan is decreased, some people survive into adolescence or early adulthood. With proper treatment, some affected people may live normal lives.
People who have spinal muscular atrophy (SMA) don't create enough survival motor neuron (SMN) protein because of a mutation in the survival motor neuron gene 1 (SMN1). The motor neuron cells weaken and finally die if this protein is absent. Debilitating and sometimes deadly muscular weakness results from this. Increasing the body's supply of the survival motor neuron protein is one method of treating SMA.
This region has been active for some time in propagating awareness and understanding of SMA. Seven non-profit national patient organizations working in the SMA and neuromuscular illness fields came together to form the organization SMA Europe. It has expanded through time to include 13 full members. No medication for the management of SMA was licensed or in the clinical trial stage when the organization was established in 2007.
The Germany market dominated the Europe Spinal Muscular Atrophy Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $737.8 million by 2028. The UK market is anticipated to grow at a CAGR of 17.1% during (2022-2028). Additionally, The France market would exhibit a CAGR of 19% during (2022-2028).
Based on Type, the market is segmented into Type 1, Type 2, Type 3 and Type 4. Based on Route of Administration, the market is segmented into Injection and Oral. Based on Treatment Type, the market is segmented into Drug and Gene Therapy. Based on Drug Type, the market is segmented into Spinraza, Zolgensma (AVXS-101), Evrysdi and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Biogen, Inc., Novartis AG, Ionis Pharmaceuticals, Inc., PTC Therapeutics, Inc., NMD Pharma A/S, Scholar Rock, Inc. (Scholar Rock Holding Corporation), Cytokinetics, Inc., Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.), Astellas Pharma, Inc., and F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
Depending on the shape and kind of SMA, the prognosis varies. Certain kinds are lethal if left untreated. Long periods of stability may be apparent in a person, but without therapy, improvement cannot be anticipated. While some SMA patients pass away in infancy, others can survive into adolescence or early adulthood.
For infants with SMA Type I, the majority pass away within the initial two years. The prognosis for average lifespan or independent walking or standing in individuals with SMA Type II approximately coincides with the age at which symptoms first appear, older children typically have less serious symptoms. Although the average lifespan is decreased, some people survive into adolescence or early adulthood. With proper treatment, some affected people may live normal lives.
People who have spinal muscular atrophy (SMA) don't create enough survival motor neuron (SMN) protein because of a mutation in the survival motor neuron gene 1 (SMN1). The motor neuron cells weaken and finally die if this protein is absent. Debilitating and sometimes deadly muscular weakness results from this. Increasing the body's supply of the survival motor neuron protein is one method of treating SMA.
This region has been active for some time in propagating awareness and understanding of SMA. Seven non-profit national patient organizations working in the SMA and neuromuscular illness fields came together to form the organization SMA Europe. It has expanded through time to include 13 full members. No medication for the management of SMA was licensed or in the clinical trial stage when the organization was established in 2007.
The Germany market dominated the Europe Spinal Muscular Atrophy Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $737.8 million by 2028. The UK market is anticipated to grow at a CAGR of 17.1% during (2022-2028). Additionally, The France market would exhibit a CAGR of 19% during (2022-2028).
Based on Type, the market is segmented into Type 1, Type 2, Type 3 and Type 4. Based on Route of Administration, the market is segmented into Injection and Oral. Based on Treatment Type, the market is segmented into Drug and Gene Therapy. Based on Drug Type, the market is segmented into Spinraza, Zolgensma (AVXS-101), Evrysdi and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Biogen, Inc., Novartis AG, Ionis Pharmaceuticals, Inc., PTC Therapeutics, Inc., NMD Pharma A/S, Scholar Rock, Inc. (Scholar Rock Holding Corporation), Cytokinetics, Inc., Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.), Astellas Pharma, Inc., and F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
Scope of the Study
By Type
- Type 1
- Type 2
- Type 3
- Type 4
By Route of Administration
- Injection
- Oral
By Treatment Type
- Drug
- Spinraza
- Zolgensma (AVXS-101)
- Evrysdi
- Others
- Gene Therapy
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Biogen, Inc.
- Novartis AG
- Ionis Pharmaceuticals, Inc.
- PTC Therapeutics, Inc.
- NMD Pharma A/S
- Scholar Rock, Inc. (Scholar Rock Holding Corporation)
- Cytokinetics, Inc.
- Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.)
- Astellas Pharma, Inc.
- F.Hoffmann-La Roche Ltd. (Genentech, Inc.)
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. Europe Spinal Muscular Atrophy Treatment Market by Type
Chapter 5. Europe Spinal Muscular Atrophy Treatment Market by Route of Administration
Chapter 6. Europe Spinal Muscular Atrophy Treatment Market by Treatment Type
Chapter 7. Europe Spinal Muscular Atrophy Treatment Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Biogen, Inc.
- Novartis AG
- Ionis Pharmaceuticals, Inc.
- PTC Therapeutics, Inc.
- NMD Pharma A/S
- Scholar Rock, Inc. (Scholar Rock Holding Corporation)
- Cytokinetics, Inc.
- Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.)
- Astellas Pharma, Inc.
- F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
Methodology
LOADING...
